Baseline Characteristics, Enitociclib Response, and Pharmacokinetic Properties of Patients with DH-DLBCL and Other MYC+ NHL (n = 15) Treated with 30 mg Enitociclib i.v. Once Weekly. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.